<think> Okay, let's tackle this job title translation. The user wants everything translated except brand names and acronyms. The original title is "Director, Nonclinical Due Diligence & External Innovation". First, "Director" is straightforward. In many contexts, it's the same in English, but maybe in some languages it could be different. But since the target is English, — CSL Behring
NewCHF 68'000 - 103'000
CSL Behring · Bern (BE)
- Location
- Bern
- Contract
- full-time
- Posted
- Yesterday
SalaryCHF 68'000 - 103'000
Role overview
The Director Non-Clinical Due Diligence & External Evaluations provides scientific leadership for nonclinical due diligence supporting CSL’s in‑licensing, acquisitions, and strategic collaborations.
The role ensures integrated, objective, and decision‑relevant evaluations of nonclinical pharmacology, PK/QSP, and toxicology data to identify development risks, data gaps, and mitigation strategies and to inform portfolio decisions.
The incumbent will further act as nonclinical representative for selected Research programs and support oversight of nonclinical strategies and programs across all Therapeutic Areas.
- The Director Non-Clinical Due Diligence & External Evaluations provides scientific leadership for nonclinical due diligence supporting CSL’s in‑licensing, acquisitions, and strategic collaborations.
- The role ensures integrated, objective, and decision‑relevant evaluations of nonclinical pharmacology, PK/QSP, and toxicology data to identify development risks, data gaps, and mitigation strategies and to inform portfolio decisions.
- and accountabilities
- Leads operational execution of nonclinical due diligence for assigned opportunities.
- Education:
- Advanced degree (Ph.D., D.V.M., or equivalent) in toxicology, pharmacology, or a related field
Main responsibilities
- and accountabilities
- Leads operational execution of nonclinical due diligence for assigned opportunities.
- Acts as hands‑on scientific integrator, translating expert input into clear risk narratives.
- Trusted subject‑matter lead for nonclinical DD on individual deals.
- Lead end-to-end nonclinical due diligence for individual assets or transactions, from request through final governance readout.
- Integrate input from Toxicology, PK/QSP, Nonclinical Pharmacology, and external experts into a single, coherent scientific assessment.
- Identify FIH‑enabling gaps, translational risks, and regulatory limitations, with clear mitigation proposals.
- Prepare high‑quality DD reports, executive summaries, and risk tables for governance review.
- Act as NCD scientific interface to Business Development and Therapeutic Area teams at the project level.
- Contribute to maintenance and continuous improvement of nonclinical DD frameworks and templates.
Key requirements
- Education:
- Advanced degree (Ph.D., D.V.M., or equivalent) in toxicology, pharmacology, or a related field
- Toxicology training, board certification preferred Experience :
- Experience in nonclinical development (10+ years) with proven experience in due diligence or external innovation, ideally across various geographies.
- Strong understanding of FIH‑enabling nonclinical requirements, particularly for biologics and complex modalities.
- Ability to communicate complex scientific risk clearly to non‑expert stakeholders.
- Experience across multiple therapeutic areas and modalities is highly desirable. Competencies:
- Proven ability to work effectively both independently or in a team setting, and to meet set goals by managing own timelines.
- Experience in working in cross-functional, multicultural and international teams.
- Excellent communication and analytical skills.
- Experience in analyzing and presenting research results to scientific and professional audiences.
Company and context
- Strong planning and organizational skills.
- Ability to work successfully in a matrix organizational structure.
- Strong negotiation skills and ability to identify and engage internal and external expertise as needed.
- Good understanding of drug development process, strong knowledge of ICH/GLP Fluent in English, oral and written;
- The role requires onsite presence 3 days per week.
- The role can be based in Zurich, Switzerland or Waltham, USA. About CSL Behring
- CSL Behring is a global biotherapeutics leader driven by our promise to save lives.
- Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
- We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
- CSL Behring operates one of the world’s largest p
Additional details
- Responsibilities and accountabilities
- Escalates complex or high‑impact issues to Head of NCD Chair of “NCD Review Committee”
- Toxicology training, board certification preferred
- Experience across multiple therapeutic areas and modalities is highly desirable.
- Good understanding of drug development process, strong knowledge of ICH/GLP Fluent in English, oral and written;
- The role can be based in Zurich, Switzerland or Waltham, USA.
Notes and original content
- Escalates complex or high‑impact issues to Head of NCD
- Chair of “NCD Review Committee”
- Qualifications:
- Experience :
- Competencies:
- Good understanding of drug development process, strong knowledge of ICH/GLP
- Fluent in English, oral and written;
- About CSL Behring
